G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics announced that it will be continuing its Phase III breast cancer trial for its drug Cosela following an interim analysis, pushing back a data readout and sending its stock $GTHX down nearly 40%.
G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference.
January 2024 Inducement Grants
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent
New data at the 2023 SABCS explore the long-term impact of trilaciclib on survival outcomes in patients with metastatic TNBC
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
Trilaciclib Reduces Hospitalizations and Myelosuppressive Events in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and May Improve Survival
G1 Therapeutics to release 3Q23 financial results on November 1, 2023